journal article·2023-12Open access

Combination of irinotecan silicasome nanoparticles with radiation therapy sensitizes immunotherapy by modulating the activation of the cGAS/STING pathway for colorectal cancer

Lu Wang, Tianyu Zhang, Yile Zheng, Yuting Li, Xiyuan Tang, Qianping Chen, Wei Mao, Weiwei Li, Xiangsheng Liu, Ji Zhu

Abstract

Our previous clinical trial (Identifier: NCT02605265) revealed that addition of irinotecan (IRIN) to neoadjuvant chemoradiotherapy for rectal cancer could improve the curative effect. However, the adverse effects caused by IRIN limited the wide application of IRIN chemoradiotherapy. This study aimed to explore the mechanism under the synergistic effects of IRIN plus radiation therapy in colorectal cancer (CRC) cells and optimization of IRIN delivery via a silicasome nanocarrier in vivo. Our results revealed that compared with single IRIN or radiation treatment, IRIN combined with radiation therapy remarkably activated the intracellular cGAS/STING pathway, and promoted the expression levels of major histocompatibility complex class I (MHC-I) and programmed death ligand 1 (PD-L1). Further, a silicasome (mesoporous silica nanoparticle coated with lipid bilayer) nanocarrier was utilized to improve the delivery of IRIN with enhanced efficacy and reduced side effects. In the MC38 CRC syngeneic tumor model, IRIN silicasome combined with radiation therapy demonstrated a greater antitumor efficacy than free IRIN plus radiation therapy. Flow cytometry showed the increased number of CD4+ T cells, CD8+ T cells, and dendritic cells (DCs) in tumor in the IRIN silicasome plus radiation group. The immunofluorescence staining further confirmed the activated immune microenvironment with the elevated interferon-γ (IFN-γ) deposition. Besides, the antitumor effect of IRIN silicasome plus radiation therapy was synergistically enhanced by anti-PD-1 immunotherapy. These findings indicated that the combination of IRIN silicasome with radiation therapy could sensitize immunotherapy by manipulating the cGAS/STING pathway serving as a new strategy for CRC treatment.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: interferon and immune responses · Immune Cell Function and Interaction · Immunotherapy and Immune Responses

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (63)

Show source-provided references
1. Estimated Deaths · 2023
2. The NCCN rectal cancer clinical practice guidelines in oncology (version 5 2023) [EB/OL] · 2023
3. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the international watch & wait database (Iwwd): an international multicentre registry study10.1016/S0140-6736(18)31078-X ↗
4. Pathological complete response following pre-operative chemoradiotherapy in rectal cancer: analysis of phase II/III trials10.1259/bjr/86650067 ↗
5. Cancer.net. Colorectal Cancer: Statistics, Available at: https://www.cancer.net/cancer-types/colorectal-cancer/statistics. Accessed: February 13, 2023.
6. A phase II study of preoperative radiotherapy and concomitant weekly irinotecan in combination with protracted venous infusion 5-fluorouracil, for resectable locally advanced rectal cancer10.1016/j.ijrobp.2006.04.007 ↗
7. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer10.1038/sj.bjc.6603645 ↗
8. Preoperative downstaging chemoradiation with concurrent irinotecan and capecitabine in MRI-defined locally advanced rectal cancer: a phase I trial (NWCOG-2)10.1038/sj.bjc.6605258 ↗
9. Preoperative chemoradiation with irinotecan and capecitabine in patients with locally advanced resectable rectal cancer: long-term results of a Phase II study10.1016/j.ijrobp.2009.12.073 ↗
10. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer10.1200/JCO.2005.04.171 ↗
11. Preoperative chemoradiotherapy using concurrent capecitabine and irinotecan in magnetic resonance imaging-defined locally advanced rectal cancer: impact on long-term clinical outcomes10.1200/JCO.2010.29.7697 ↗
12. Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer10.1016/j.ijrobp.2011.05.027 ↗
13. Efficacy endpoints of radiation therapy group protocol 0247: a randomized, phase 2 study of neoadjuvant radiation therapy plus concurrent capecitabine and irinotecan or capecitabine and oxaliplatin for patients with locally advanced rectal cancer10.1016/j.ijrobp.2014.09.031 ↗
14. Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients10.1002/cncr.25735 ↗
15. Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan10.1200/JCO.2004.07.173 ↗
16. Multicenter, randomized, phase III trial of neoadjuvant chemoradiation with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer10.1200/JCO.20.01932 ↗
17. Mismatch repair deficiency predicts response of solid tumors to pd-1 blockade10.1126/science.aan6733 ↗
18. Tumour infiltrating lymphocytes and apoptosis are independent features in colorectal cancer stratified according to microsatellite instability status10.1136/gut.48.3.360 ↗
19. Pembrolizumab in microsatellite-Instability-High advanced colorectal cancer10.1056/NEJMoa2017699 ↗
20. Deficient mismatch repair/microsatellite unstable colorectal cancer: diagnosis, prognosis and treatment10.1016/j.ejca.2022.07.020 ↗
21. Inflammatory microenvironment remodelling by tumour cells after radiotherapy10.1038/s41568-020-0246-1 ↗
22. Cyclic GMP-AMP synthase is a cytosolic DNA sensor that activates the type I interferon pathway10.1126/science.1232458 ↗
23. STING is a direct innate immune sensor of cyclic di-GMP10.1038/nature10429 ↗
24. Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer10.1158/2159-8290.CD-18-1020 ↗
25. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity10.1172/JCI127471 ↗
26. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer10.1021/acsnano.8b06164 ↗
27. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-110.1002/advs.202002147 ↗
28. Effects of radiation on tumor vasculature10.1002/mc.23360 ↗
29. Predicting tumour radiosensitivity to deliver precision radiation10.1038/s41571-022-00709-y ↗
30. Exploiting DNA replication stress for cancer treatment10.1158/0008-5472.CAN-18-3631 ↗
31. ROS and the DNA damage response in cancer10.1016/j.redox.2018.101084 ↗
32. SynergyFinder 2.0: visual analytics of multi-drug combination synergies10.1093/nar/gkaa216 ↗
33. Evaluation of drug combination effect using a Bliss independence dose-response surface model10.1080/19466315.2018.1437071 ↗
34. Targeting the DNA damage response in immuno-oncology: developments and opportunities10.1038/s41568-021-00386-6 ↗
35. The cGAS-STING pathway and cancer
36. DNA breaks and chromosome pulverization from errors in mitosis10.1038/nature10802 ↗
37. cGAS/STING axis mediates a topoisomerase II inhibitor-induced tumor immunogenicity10.1172/JCI127471 ↗
38. Uncoupling interferon signaling and antigen presentation to overcome immunotherapy resistance due to JAK1 loss in melanoma10.1126/scitranslmed.abb0152 ↗
39. Chemoradiation increases PD-L1 expression in certain melanoma and glioblastoma cells10.3389/fimmu.2016.00610 ↗
40. Topoisomerase I inhibitor, irinotecan, depletes regulatory T cells and up-regulates MHC class I and PD-L1 expression, resulting in a supra-additive antitumor effect when combined with anti-PD-L1 antibodies10.18632/oncotarget.25830 ↗
41. ISG15 in antiviral immunity and beyond10.1038/s41579-018-0020-5 ↗
42. NLRC5 elicits antitumor immunity by enhancing processing and presentation of tumor antigens to CD8(+) T lymphocytes10.1080/2162402X.2016.1151593 ↗
43. NLR family member NLRC5 is a transcriptional regulator of MHC class I genes10.1073/pnas.1008684107 ↗
44. Tumor-targeted silencing of the peptide transporter TAP induces potent antitumor immunity10.1038/s41467-019-11728-2 ↗
45. Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy10.1158/0008-5472.CAN-05-4007 ↗
46. Irinotecan delivery by lipid-coated mesoporous silica nanoparticles shows improved efficacy and safety over liposomes for pancreatic cancer10.1021/acsnano.5b07781 ↗
47. Tumor-penetrating peptide enhances transcytosis of silicasome-based chemotherapy for pancreatic cancer10.1172/JCI92284 ↗
48. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity10.1038/ncomms15618 ↗
49. cGAS/STING cross-talks with cell cycle and potentiates cancer immunotherapy10.1016/j.ymthe.2022.01.044 ↗
50. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, 59phase 3 trial10.1016/S0140-6736(15)00986-1 ↗
51. PEPCOL: a GERCOR randomized phase II study of nanoliposomal irinotecan PEP02 (MM-398) or irinotecan with leucovorin/5-fluorouracil as second-line therapy in metastatic colorectal cancer10.1002/cam4.635 ↗
52. Immune checkpoint inhibition in syngeneic mouse cancer models by a silicasome nanocarrier delivering a GSK3 inhibitor10.1016/j.biomaterials.2020.120635 ↗
53. Use of ratiometrically designed nanocarrier targeting CDK4/6 and autophagy pathways for effective pancreatic cancer treatment10.1038/s41467-020-17996-7 ↗
54. Safety considerations of cancer nanomedicine-A Key step toward translation10.1002/smll.202000673 ↗
55. Consideration for the scale-up manufacture of nanotherapeutics-A critical step for technology transfer10.1002/VIW.20200190 ↗
56. Ionizing radiation increases the endothelial permeability and the transendothelial migration of tumor cells through ADAM10‐activation and subsequent degradation of VE‐cadherin10.1186/s12885-019-6219-7 ↗
57. Ionising radiation increases permeability of endothelium through ADAM10‐mediated cleavage of VE‐cadherin10.18632/oncotarget.18282 ↗
58. Topoisomerase 1 inhibition promotes cyclic GMP-AMP synthase-dependent antiviral responses10.1128/mBio.01611-17 ↗
59. Topoisomerase I poison-triggered immune gene activation is markedly reduced in human small-cell lung cancers by impairment of the cGAS/STING pathway10.1038/s41416-022-01894-4 ↗
60. DNA exonuclease Trex1 regulates radiotherapy-induced tumour immunogenicity10.1038/ncomms15618 ↗
61. Mitotic progression following DNA damage enables pattern recognition within micronuclei10.1038/nature23470 ↗
62. Effects of radiation on tumor vasculature10.1002/mc.23360 ↗
63. An add-in program for pharmacokinetic and pharmacodynamic data analysis in microsoft excel10.1016/j.cmpb.2010.01.007 ↗